Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV: Department of Health and Human Services 2023 [updated March 23, 2023; cited 2023 June 6]. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf.
   Google Scholar
• HIV.gov. Types of providers 2018 [updated May 21, 2018; cited 2023 May 16]. Available from: https://www.hiv.gov/hiv-basics/starting-hiv-care/find-a-provider/types-of-providers/.
   Google Scholar
• Kolakowska A, Maresca AF, Collins IJ, et al. Update on adverse effects of HIV integrase inhibitors. Curr Treat Options Infect Dis. 2019;11(4):372–387. doi: 10.1007/s40506-019-00203-7.
   PubMedGoogle Scholar
• Eaton EF, Tamhane A, Davy-Mendez T, et al. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure. AIDS. 2018;32(3):347–355. doi: 10.1097/QAD.0000000000001708.
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Isentress package insert [package insert] 2019; [cited 2020 May 22]. Available from: https://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf.
   Google Scholar
• Gilead Sciences Inc. Vitekta package insert [package insert] 2014; [cited 2020 May 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203093s000lbl.pdf.
   Google Scholar
• GlaxoSmithKline. Tivicay package insert [package insert] 2013; [cited 2020 May 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf.
   Google Scholar
• Gilead Sciences Inc. Biktarvy package insert [package insert] 2018; [cited 2022 April 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf.
   Google Scholar
• Shah S, Hindley L, Hill A. Are new antiretroviral treatments increasing the risk of weight gain? Drugs. 2021;81(3):299–315. doi: 10.1007/s40265-020-01457-y.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Diseases. 2020;71(6):1379–1389. doi: 10.1093/cid/ciz999.
   PubMed Web of Science ®Google Scholar
• Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2021;143(21):e984–e1010. doi: 10.1161/CIR.0000000000000973.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5(4):e10106. doi: 10.1371/journal.pone.0010106.
   PubMed Web of Science ®Google Scholar
• Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration. Lancet. 2014;384(9939):241–248. doi: 10.1016/S0140-6736(14)60604-8.
   PubMed Web of Science ®Google Scholar
• Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117(2):214–220. doi: 10.1016/j.amjcard.2015.10.030.
   PubMed Web of Science ®Google Scholar
• Hester EK, Greenlee S, Durham SH. Weight changes with integrase strand transfer inhibitor therapy in the management of HIV infection: a systematic review. Ann Pharmacother. 2022;56(11):1237–1249. doi: 10.1177/10600280211073321.
   Web of Science ®Google Scholar
• Bourgi K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23(4):e25484. doi: 10.1002/jia2.25484.
   PubMed Web of Science ®Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267–1274. doi: 10.1093/cid/ciz407.
   PubMed Web of Science ®Google Scholar
• Ruderman SA, Crane HM, Nance RM, et al. Brief report: weight gain following ART initiation in ART-Naïve people living with HIV in the current treatment era. J Acquir Immune Defic Syndr. 2021;86(3):339–343. doi: 10.1097/QAI.0000000000002556.
   PubMed Web of Science ®Google Scholar
• Emond B, Rossi C, Côté-Sergent A, et al. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States. Curr Med Res Opin. 2022;38(2):287–298. doi: 10.1080/03007995.2021.2007006.
   PubMed Web of Science ®Google Scholar
• Emond B, Rossi C, Côté-Sergent A, et al. Weight change and predictors of weight change among patients initiated on darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide: a Real-World retrospective study. J Health Econ Outcomes Res. 2021;8(1):88–98. doi: 10.36469/jheor.2021.24535.
   PubMedGoogle Scholar
• Ober NS, Grubmuller J, Farrell M, et al. System and method for generating de-identified health care data. Google Patents. 2008.
   Google Scholar
• Zubeldia K, Romney GW. Anonymously linking a plurality of data records. Google Patents. 2002.
   Google Scholar
• Hines DM, Ding Y, Wade RL, et al. Treatment adherence and persistence among HIV-1 patients newly starting treatment. Patient Prefer Adherence. 2019;13:1927–1939. doi: 10.2147/PPA.S207908.
   PubMed Web of Science ®Google Scholar
• Rosenblatt L, Buikema AR, Seare J, et al. Economic outcomes of First-Line regimen switching among stable patients with HIV. J Manag Care Spec Pharm. 2017;23(7):725–734. Juldoi: 10.18553/jmcp.2017.16403.
   PubMed Web of Science ®Google Scholar
• Sax PE, Meyers JL, Mugavero M, et al. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7(2):e31591. doi: 10.1371/journal.pone.0031591.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. Novdoi: 10.1097/01.mlr.0000182534.19832.83.
   PubMed Web of Science ®Google Scholar
• Lindstrom MJ, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics. 1990;46(3):673–687. doi: 10.2307/2532087.
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Isabel Pereira B, Moyle G, et al. Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of age. AIDS Care. 2022;34(4):542–544. Aprdoi: 10.1080/09540121.2021.1935438.
   PubMed Web of Science ®Google Scholar
• Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258–271. doi: 10.1016/S0140-6736(14)60164-1.
   PubMed Web of Science ®Google Scholar
• Shoko C, Chikobvu D. A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy. BMC Infect Dis. 2019;19(1):169. doi: 10.1186/s12879-019-3781-1.
   PubMed Web of Science ®Google Scholar
• Ruderman S, Nance R, Whitney B, et al. editors. Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naïve people living with HIV (PLWH). 17th European AIDS Conference; 2019; Basel, Switzerland.
   Google Scholar
• Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364–e372. doi: 10.1016/S2352-3018(19)30080-3.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e355–e363. doi: 10.1016/S2352-3018(19)30077-3.
   PubMed Web of Science ®Google Scholar
• Yuh B, Tate J, Butt AA, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1852–1859. doi: 10.1093/cid/civ192.
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–622. doi: 10.1001/jamainternmed.2013.3728.
   PubMed Web of Science ®Google Scholar
• Barnes RP, Lacson JCA, Bahrami H. HIV infection and risk of cardiovascular diseases beyond coronary artery disease. Curr Atheroscler Rep. 2017;19(5):20–20. doi: 10.1007/s11883-017-0652-3.
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Chang CH, Skanderson M, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study. JAMA Cardiol. 2017;2(5):536–546. doi: 10.1001/jamacardio.2017.0264.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Duncan MS, Alcorn CW, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease. Circulation. 2018;138(3):255–265. doi: 10.1161/CIRCULATIONAHA.117.032647.
   PubMed Web of Science ®Google Scholar
• Lake JE, Wu K, Erlandson KM, et al. editors. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Conference on Retroviruses and Opportunistic Infections; 2019 Feb 26; Seattle, Washington2020/02/27).
   Google Scholar
• Koethe J, Bian A, Rebeiro PF, et al. editors. Greater weight gain after switch to InSTI-based regimen from NNRTI vs PI regimens. Conference on Retroviruses and Opportunistic Infections; 2020; Boston, MA.
   Google Scholar
• Menard A, Meddeb L, Tissot-Dupont H, et al. Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. 2017;31(10):1499–1500. doi: 10.1097/QAD.0000000000001495.
   PubMed Web of Science ®Google Scholar
• Rebeiro PF, Jenkins CA, Bian A, et al. Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with HIV in the US and Canada. Clin Infect Dis. 2021;73(7):e2234–e2242.
   Web of Science ®Google Scholar
• Hindley L, McCann K, Sokhela S, et al. Predicted 10-year risks of cardiovascular disease and diabetes in the ADVANCE trial. CROI 2021, Conference on Retroviruses and Opportunistic Infections, March 6–10, 2021.
   Google Scholar
• Pereira B, Mazzitelli M, Milinkovic A, et al. Evaluation of a clinic dedicated to people aging with HIV at chelsea and westminster hospital: results of a 10-Year experience. AIDS Res Hum Retroviruses. 2022;38(3):188–197. doi: 10.1089/AID.2021.0083.
   PubMed Web of Science ®Google Scholar
• O’Halloran JS, Olsen M, Powderly W. Incident diabetes associated with integrase strand transfer inhibitor initiation. CROI 2021, Conference on Retroviruses and Opportunistic Infections, March 6–10, 2021. 2021.
   Google Scholar